Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HTR2B | P41595 | 4/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.53 |
| ▸ | PARP1 | P09874 | 6/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.53 |
| ▸ | GRM5 | P41594 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882012 | 0.88 | PARP10 (0.53) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL4715588 | 0.88 | PARP10 (0.53) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL30870989 | 0.84 | PARP10 (0.49) | PARP10PARP1PARP11GRM5KDM4E | |
| SCHEMBL28651773 | 0.83 | HTR2A (0.49) | HTR2AHTR2CHTR2BGRM5KDM4E | |
| SCHEMBL5807937 | 0.83 | ACHE (0.51) | PARP10PARP1PARP11GRM5KDM4E | |
| SCHEMBL15814334 | 0.83 | NCOA1 (0.52) | PARP10PARP1PARP11GRM5KDM4E | |
| SCHEMBL31167714 | 0.83 | PARP10 (0.47) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL15831695 | 0.83 | PARP10 (0.47) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL29990474 | 0.81 | PARP10 (0.49) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL24040090 | 0.81 | PARP10 (0.49) | HTR2AHTR2CHTR2BPARP10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| WO-2024240726-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-11-28 | — | — | WO | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-113493438-B | Tetrahydroisoquinoline compounds | 南京再明医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| CN-113493438-A | Tetrahydroisoquinoline compounds | 江苏先声药业有限公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2265587-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009105206-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | HTR2A 783/4885HTR2C 319/4885HTR2B 1779/4885 |
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | HTR2A 18/4885HTR2C 37/4885HTR2B 51/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | HTR2A 725/4885HTR2C 1133/4885HTR2B 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.